BridgeMD
Phase 3b/4 Study in Rheumatoid Arthritis
EU CTIS ID: 2023-508022-10-00
What this study is testing
To compare baricitinib (combined dose groups) to TNF inhibitors with respect to the risk of VTE (Venous Thromboembolism)
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants must have at least one of the following characteristics: documented evidence of a VTE prior to this study, At least 60 years of age, A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²) ,Or age 50 to less than 60 years and BMI 25 to less than 30 kg/m².
- Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic).
You likely can't join if
- Participant should have no reason to not take a TNF inhibitor.
- Participants must not be pregnant or breastfeeding.
- Participants must not have had more than one VTE.
- Participants must not have cancer.
- Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness.
- Participants must not have had a live vaccine within four weeks of study start.
See the full eligibility criteria
- Participants must have at least one of the following characteristics: documented evidence of a VTE prior to this study, At least 60 years of age, A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²) ,Or age 50 to less than 60 years and BMI 25 to less than 30 kg/m².
- Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic).
- Participant should have no reason to not take a TNF inhibitor.
- Participants must not be pregnant or breastfeeding.
- Participants must not have had more than one VTE.
- Participants must not have cancer.
- Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness.
- Participants must not have had a live vaccine within four weeks of study start.
- Participants must not have participated in any other clinical trial within four weeks of study start.
- Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year.
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- Israel
- United States
- Switzerland
- Australia
- Russian Federation
- South Africa
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; Israel; United States; Switzerland; Australia; Russian Federation and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.